Helping adults at bars in Kenya and Uganda get and stay on HIV prevention medicines
Innovative strategies to promote biomedical HIV prevention uptake and retention among high-risk adults at drinking venues in Kenya and Uganda
This project tries new ways to reach adults who drink at bars in Kenya and Uganda so they get and remain on HIV prevention like PrEP and PEP.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11381521 on NIH RePORTER |
What this research studies
From your perspective, researchers will visit drinking venues in Kenya and Uganda and offer combined screenings for multiple diseases so HIV testing feels less stigmatized. They plan to use this multi-disease mobilization to recruit over 2,000 adults and link people who test negative but are at risk to PrEP or PEP services. The team will support people to start prevention and follow them over time to help them stay on the medicines. Activities happen in-person at selected community drinking venues and local clinics.
Who could benefit from this research
Good fit: Ideal candidates are adults (21+) who frequent drinking venues in the participating communities of Kenya or Uganda and are at increased risk for HIV.
Not a fit: People who do not visit the targeted drinking venues, are not at increased HIV risk, or who already need HIV treatment rather than prevention are unlikely to benefit directly.
Why it matters
Potential benefit: If successful, more people at high risk could learn their HIV status, start PrEP/PEP, and stay on prevention, lowering their chance of getting HIV.
How similar studies have performed: Venue-based multi-disease screening has previously boosted HIV testing uptake, but using these methods specifically to increase PrEP/PEP start and long-term retention is relatively new.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Chamie, Gabriel — University of California, San Francisco
- Study coordinator: Chamie, Gabriel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.